GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence

Major bleeding events (adapted ISTH standard)

Time frame: up to 1.5 years(max 3 years)

Non-major bleeding events(without Major Bleeding complications)

Time frame: up to 1.5 years(max 3 years)

Composite of symptomatic stroke(ischemic or hemorrhagic),systemic embolism,myocardial infarction/unstable angina pectoris and cardiovascular death

Time frame: up to 1.5 years(max 3 years)

Symptomatic stroke (ischemic or hemorrhagic)

Time frame: up to 1.5 years(max 3 years)

Symptomatic ischemic stroke

Time frame: up to 1.5 years(max 3 years)

Symptomatic hemorrhagic stroke

Time frame: up to 1.5 years(max 3 years)

Systemic embolism

Time frame: up to 1.5 years(max 3 years)

Acute myocardial infarction/unstable angina pectoris

Time frame: up to 1.5 years(max 3 years)

Cardiovascular death

Time frame: up to 1.5 years(max 3 years)

Deep vein thrombosis/pulmonary thromboembolism

Time frame: up to 1.5 years(max 3 years)

Transient ischemic attack

Time frame: up to 1.5 years(max 3 years)

Percutaneous coronary intervention /coronary artery bypass grafting

Time frame: up to 1.5 years(max 3 years)

All cause death

Time frame: up to 1.5 years(max 3 years)

Comparison of primary outcome (composite of symptomatic stroke(ischemic/hemorrhagic) and systemic embolism) rate and Major Bleeding complications (adapted ISTH standard)rate between EXPAND study and FUSHIMI AF registry

Time frame: up to 1.5 years(max 3 years)

Adverse Event excluding hemorrhagic events

Time frame: up to 1.5 years(max 3 years)

Patients adherence related with stroke or systemic embolism

Time frame: up to 1.5 years(max 3 years)

Correlation with CHADS2 score or other risk factors and outcome events in Japanese patients who administered Rivaroxaban

Time frame: up to 1.5 years(max 3 years)